Preemptive antiviral therapy in lung transplantation from hepatitis C donors results in a rapid and sustained virologic response.

ABSTRACT:

Objective

The study objective was to assess the safety and efficacy of a preemptive direct-acting antiviral therapy in lung transplants from hepatitis C virus donors to uninfected recipients.

Methods

This study is a prospective, open-label, nonrandomized, pilot trial. Recipients of hepatitis C virus nucleic acid test positive donor lungs underwent preemptive direct-acting antiviral therapy with glecaprevir 300 mg/pibrentasvir 120 mg for 8 weeks from January 1, 2019, to December 31, 2020. Recipients of nucleic acid test positive lungs were compared with recipients of lungs from nucleic acid test negative donors. Primary end points were Kaplan-Meier survival and sustained virologic response. Secondary outcomes included primary graft dysfunction, rejection, and infection.

Re

SUBMITTER: Villavicencio MA 

PROVIDER: S-EPMC10328796 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature